For years, active smoking has been treated as a surgical red flag, especially in aesthetic procedures where perfusion and wound healing directly impact the final result. Rhinoplasty, with its intricate vascular demands and the critical need for predictable tissue healing, has been no exception. But recent data from a retrospective study published in Plastic and Reconstructive Surgery may challenge the reflex to delay or deny surgery based solely on smoking status. Surgical Aesthetics 411 this week takes a closer look at the latest data concerning rhinoplasty in smokers and reviews the clinical implications.
What the Data Really Shows
This study evaluated 1,884 open rhinoplasty patients treated between 2014 and 2022, dividing them into active smokers (80 patients), former smokers (39), and nonsmokers (1,765). All patients had a minimum of 12 months follow-up, with an average follow-up of nearly two years.
The study found that smokers had a 3.8% revision rate compared to 3.3% in nonsmokers, a difference too small to be clinically meaningful. Postoperative infections requiring antibiotics for cellulitis were slightly more common in smokers (3.8% vs. 1.6%), but all cases resolved without long-term issues, and there were no instances of wound breakdown or necrosis. Overall, wound healing outcomes were comparable between smokers and nonsmokers.
From a data standpoint, the risks commonly attributed to smoking did not materialize in any meaningful way across these outcomes.
Clinical Implications: What Should Change?
The nasal region benefits from a robust, redundant vascular network, an anatomical safeguard that might help explain the unexpectedly comparable complication rates. This resilience makes rhinoplasty somewhat unique among aesthetic surgeries in smokers.
That doesn’t mean smoking is irrelevant. Nicotine still causes vasoconstriction, impairs angiogenesis, and inhibits fibroblast function. But the data here suggests these effects may not translate into a higher risk profile in all patients, particularly when experienced surgeons and optimized protocols are involved.
This study doesn’t argue for relaxing standards. Instead, it supports more nuanced risk assessment:
- Continue to encourage cessation, but consider whether it’s worth delaying a motivated patient over what may be marginal statistical risks.
- Use the data to guide preoperative discussions. If a smoker insists on surgery without quitting, the conversation shifts from a blanket denial to an informed risk-benefit analysis.
- Optimize intraoperative technique to minimize tissue trauma and preserve vascular supply. In smokers, atraumatic handling and precise dissection may be even more critical.
Risk Stratification, Not Risk Elimination
A “no surgery for smokers” policy may no longer be tenable, at least not for rhinoplasty. These findings suggest that smoking status alone shouldn’t disqualify patients from surgery, provided that they are well-informed, low-risk otherwise, and fully engaged in postoperative care.
This is especially relevant for revision rhinoplasty patients, many of whom are older and may have a history of tobacco use. If the data shows they are not at dramatically elevated risk, surgeons can prioritize individual patient factors over rigid policy.
Bottom Line
Smoking remains a modifiable risk factor, and cessation should be encouraged whenever possible. But this study offers reassurance that, for rhinoplasty at least, smokers can be treated safely with good outcomes. It’s a call to refine (not relax) our standards, and to base preoperative decisions on data over dogma.
Your surgical decision-making should always prioritize safety and aesthetics. But don’t let outdated assumptions stand in the way of treating the right patient.
Surgical Aesthetics 411 will continue to track the science, the products, and the legal landscape so you don’t have to. Subscribe to stay ahead of the curve, cut through the marketing, and make smarter decisions in your aesthetics practice.
SOURCES: Plastic and Reconstructive Surgery
This content is intended for educational purposes only and does not substitute for clinical judgment. Treatment decisions should be based on individual patient needs, professional guidelines, and a comprehensive clinical evaluation.
